Molecular Templates Inc. (MTEM)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
0.00
-0.00 (-100.00%)
At close: Feb 07, 2025, 2:19 PM
0.11
37000.00%
After-hours Dec 24, 2024, 04:58 PM EST
undefined% (undefined)
Bid | 0.11 |
Market Cap | 1.98K |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.05 |
PE Ratio (ttm) | n/a |
Forward PE | n/a |
Analyst | n/a |
Ask | 0.11 |
Volume | 116 |
Avg. Volume (20D) | 11,379,122 |
Open | 0.00 |
Previous Close | 0.00 |
Day's Range | 0.00 - 0.00 |
52-Week Range | 0.00 - 4.12 |
Beta | undefined |
About MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cance...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2005
Employees 62
Stock Exchange NASDAQ
Ticker Symbol MTEM
Website https://www.mtem.com
Next Earnings Release
Molecular Templates Inc. is scheduled to release its earnings on Feb 18, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
1 month ago
-54.29%
Molecular Templates shares are trading lower after...
Unlock content with
Pro Subscription
3 months ago
+186.07%
Molecular Templates shares are trading higher amid volatility after the company recently announced it approved the liquidation and wind-up.